
RETRACTION

In a previous editorial on the policing of clinical trials,¹ George P. Canellos, MD, Editor-in-Chief, referred to the 1995 *Journal of Clinical Oncology* (JCO) publication of an article describing a trial of high-dose chemotherapy compared with conventional-dose therapy in metastatic breast cancer by Bezwoda et al.² That article has been widely quoted in the medical literature and in the lay press. After the revelation of inconsistencies in data reported by Dr Bezwoda in another trial in high-risk breast cancer,³ an audit of the data published in the JCO in 1995 was conducted. The results of this audit are published as a Special Article in the current issue of the JCO. As a result of the findings of this audit, the *Journal of Clinical Oncology* is formally retracting the 1995 publication.

Published online before print at <http://www.asco.org/jco/ascoindex.htm>.

REFERENCES

1. Canellos GP: The policing of clinical trials. *J Clin Oncol* 18:2353, 2000 (editorial)
2. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. *J Clin Oncol* 13:2483-2489, 1995
3. Weiss RB, Rifkin RM, Stewart FM, et al: High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study. *Lancet* 355:999-1003, 2000